Company overview
Noramco is a leading manufacturer of controlled substance active pharmaceutical ingredients (APIs), specializing in opioids, cannabinoids, and stimulants. Headquartered in Delaware, USA, the company provides DEA-compliant development and production from kilos to multi-ton scales, supporting pharmaceutical innovation with high-purity synthetic and semi-synthetic compounds. Noramco holds approvals from FDA, Health Canada, MHRA, and EMA, ensuring global regulatory compliance.
Noramco is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include noramco, controlled substance apis, opioid apis, cannabinoid apis, dea compliant manufacturing.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://noramco.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- noramco, controlled substance apis, opioid apis, cannabinoid apis, dea compliant manufacturing
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What APIs does Noramco specialize in?
- Noramco specializes in controlled substance APIs including opioids, cannabinoids, stimulants, and non-opioid products, produced from narcotic raw materials with high purity.
- What regulatory approvals does Noramco hold?
- Noramco is compliant with DEA regulations and holds approvals from United States FDA, Canada Health Canada, UK MHRA, and Europe EMA.
- What are Noramco's production capabilities and geographies?
- Headquartered in Delaware, USA, Noramco offers global operations with DEA-compliant security and capacity from kilos to multi-ton supply, including building blocks, intermediates, and custom synthesis.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
